Success Metrics

Clinical Success Rate
60.0%

Based on 3 completed trials

Completion Rate
60%(3/5)
Active Trials
1(13%)
Results Posted
100%(3 trials)
Terminated
2(25%)

Phase Distribution

Ph phase_2
4
50%
Ph phase_1
3
38%

Phase Distribution

3

Early Stage

4

Mid Stage

0

Late Stage

Phase Distribution7 total trials
Phase 1Safety & dosage
3(42.9%)
Phase 2Efficacy & side effects
4(57.1%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

50.0%

3 of 6 finished

Non-Completion Rate

50.0%

3 ended early

Currently Active

1

trials recruiting

Total Trials

8

all time

Status Distribution
Active(1)
Completed(3)
Terminated(3)
Other(1)

Detailed Status

Completed3
Terminated2
Active, not recruiting1
unknown1
Withdrawn1

Development Timeline

Analytics

Development Status

Total Trials
8
Active
1
Success Rate
60.0%
Most Advanced
Phase 2

Trials by Phase

Phase 13 (42.9%)
Phase 24 (57.1%)

Trials by Status

terminated225%
active_not_recruiting113%
completed338%
unknown113%
withdrawn113%

Recent Activity

1 active trials
Showing 5 of 8
active_not_recruitingphase_2

Phase 2 Study Evaluating the Efficacy of the Combination of DKN-01 (DKK1 Inhibitor, Leap Therapeutics) and Pembrolizumab in the Treatment of Advanced or Recurrent Endometrial Cancer

NCT05761951
terminatedphase_2

Study of the Combination of DKN-01 and Nivolumab in Previously Treated Patients With Advanced Biliary Tract Cancer (BTC)

NCT04057365
completedphase_1

Study of DKN-01 and Gemcitabine/Cisplatin in Patients With Carcinoma to Primary to the Intra- or Extra-Hepatic Biliary System or Gallbladder

NCT02375880
unknown

Expanded Access Use of DKN-01 for the Treatment of Advanced Solid Tumors

NCT04681248
completedphase_2

Phase 2 Study of DKN-01 in Colorectal Cancer

NCT05480306
View all 8 trials

Clinical Trials (8)

Showing 8 of 8 trials
NCT05761951Phase 2

Phase 2 Study Evaluating the Efficacy of the Combination of DKN-01 (DKK1 Inhibitor, Leap Therapeutics) and Pembrolizumab in the Treatment of Advanced or Recurrent Endometrial Cancer

Active Not Recruiting
NCT04057365Phase 2

Study of the Combination of DKN-01 and Nivolumab in Previously Treated Patients With Advanced Biliary Tract Cancer (BTC)

Terminated
NCT02375880Phase 1

Study of DKN-01 and Gemcitabine/Cisplatin in Patients With Carcinoma to Primary to the Intra- or Extra-Hepatic Biliary System or Gallbladder

Completed
NCT04681248

Expanded Access Use of DKN-01 for the Treatment of Advanced Solid Tumors

Unknown
NCT05480306Phase 2

Phase 2 Study of DKN-01 in Colorectal Cancer

Completed
NCT03837353Phase 1

A Parallel Arm Phase 1b/2a Study of DKN-01 as Monotherapy or in Combination With Docetaxel for the Treatment of Advanced Prostate Cancer With Elevated DKK1

Terminated
NCT03818997Phase 2

Combination of Targeted and Immunotherapy for Advanced Biliary Tract and Esophagogastric Gastric Cancer

Withdrawn
NCT01457417Phase 1

A Study of DKN-01 in Multiple Myeloma or Advanced Solid Tumors

Completed

All 8 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
8